Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors Reuters BPC 157 Research Peptide Tissue Repair Studies BioStrata BPC 157 5mg + TB 500 5mg Research Peptides PurePeptix